Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELI-002 2P in KRAS/NRAS Mutated Solid Tumors
NCT04853017Phase 1Completed
- Sponsor
- Elicio Therapeutics
- Start
- Oct 2021
- Primary completion
- Jan 2023
- Modality
- Antisense DNA, Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 1, open-label trial of ELI-002 in pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and 3 more (5 cohorts), sponsored by Elicio Therapeutics. Primary endpoint: Participant Incidence of Treatment-emergent Adverse Events Considered by the Investigator as Related to ELI-002. Started Oct 2021; status: completed.
02
Drugs
ELI-002
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)ovarian cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT04853017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04853017.